Divestitures |
6 Months Ended |
|---|---|
Dec. 31, 2022 | |
| Discontinued Operations and Disposal Groups [Abstract] | |
| Disposal Groups, Including Discontinued Operations, Disclosure | 2. Divestitures In August 2021, we sold the Cordis business to Hellman & Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in Note 6. The Cordis business operated within our Medical segment.
|